50
The deal includes the acute lymphoblastic leukemia (ALL) drug pegaspargase (Oncaspar) and late stage ALL candidate drug calaspargase pegol plus the ex-US rights fort a nano-formulation of the chemotherapeutic irinotecan (Onivyde). Servier will also receive the rights on several licenced drug candidates including CAR-T cells developed by Precision Biosciences and checkpoint modulators co-developed with Symphogen vs several targets.
Shire’s divestment comes at a time where Japan’s oncology-focussed drugmaker considers to acquire the London-based orphan drug and neurology specialist, who want to split both parts of the company. However,…